Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX*

MDM2 and MDMX function as key regulators of p53 by binding to its N terminus, inhibiting its transcriptional activity, and promoting degradation. MDM2 and MDMX overexpression or hyperactivation directly contributes to the loss of p53 function during the development of nearly 50% of human cancers. Recent studies showed that disrupting p53-MDM2 and p53-MDMX interactions can lead to robust activation of p53 but also revealed a need to develop novel dual specific or MDMX-specific inhibitors. Using phage display we identified a 12-residue peptide (pDI) with inhibitory activity against MDM2 and MDMX. The co-crystal structures of the pDI and a single mutant derivative (pDI6W) liganded with the N-terminal domains of human MDMX and MDM2 served as the basis for the design of 11 distinct pDI-derivative peptides that were tested for inhibitory potential. The best derivative (termed pDIQ) contained four amino acid substitutions and exhibited a 5-fold increase in potency over the parent peptide against both MDM2 (IC50 = 8 nm) and MDMX (IC50 = 110 nm). Further structural studies revealed key molecular features enabling the high affinity binding of the pDIQ to these proteins. These include large conformational changes of the pDIQ to reach into a hydrophobic site unique to MDMX. The findings suggest new strategies toward the rational design of small molecule inhibitors efficiently targeting MDMX.

[1]  Baoli Hu,et al.  Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. , 2007, Cancer research.

[2]  Yaolin Wang,et al.  Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. , 2004, Analytical biochemistry.

[3]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[4]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[5]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[6]  Valerie Reinke,et al.  Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 , 2001, Nature Genetics.

[7]  Hideo Negishi,et al.  Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence , 2003, Nature.

[8]  A. Fersht,et al.  The central region of HDM2 provides a second binding site for p53 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[10]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[11]  Mengjia Tang,et al.  Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[12]  A. Levine,et al.  The p53-mdm-2 autoregulatory feedback loop. , 1993, Genes & development.

[13]  Baoying Huang,et al.  Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation , 2008, Cell cycle.

[14]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[15]  A. Levine,et al.  p53 regulates maternal reproduction through LIF , 2007, Nature.

[16]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[17]  A. Levine,et al.  Mapping of the p53 and mdm-2 interaction domains. , 1993, Molecular and cellular biology.

[18]  Yu Pan,et al.  MDM2 Promotes Ubiquitination and Degradation of MDMX , 2003, Molecular and Cellular Biology.

[19]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[20]  G. Stark,et al.  Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.

[21]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[22]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[23]  G. Wahl,et al.  BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death , 2008, Cell cycle.

[24]  D. E. Anderson,et al.  Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. , 2001, Protein engineering.

[25]  Oliver Zerbe,et al.  Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .

[26]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[27]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[28]  C. Sherr.  Divorcing ARF and p53: an unsettled case , 2006, Nature Reviews Cancer.

[29]  T. Holak,et al.  Molecular Basis for the Inhibition of p53 by Mdmx , 2007, Cell cycle.

[30]  Baoli Hu,et al.  MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.

[31]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[32]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[33]  C. Prives,et al.  The p53 pathway , 1999, The Journal of pathology.

[34]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[35]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[36]  Shen-Shu Sung,et al.  Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking. , 2009, Bioorganic & medicinal chemistry letters.

[37]  Jiandong Chen,et al.  MDMX regulation of p53 response to ribosomal stress , 2006, The EMBO journal.

[38]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[39]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[40]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[41]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[42]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.